Immunex Message Board - Msg: 16371628

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: eric ross who wrote (568)	9/18/2001 9:49:34 AM
From: LemurHouse	Read Replies (1) of 656

In addition to being added to the S&P 500, as has already been posted, it announced FDA agreement to fast-track review of Enbrel for psoriatic arthritis. This will (likely) mean approval for PA indication within 6 months of application, rather than the usual 12. If memory serves, they applied for label expansion in June, which would imply FDA ruling by December. (I'm not positive about the timing of the application, so don't take my word for it.) The recent news re capacity expansion is improving the story for IMNX and has been lifting the stock, and index fund buying (S&P) should give it a short term pop. I was actually hoping to add to my position on further weakness, and so would have preferred the S&P thing to be deferred a bit. (edit) PS: I think that IMNX' situation is essentially the same as it was in March when I posted my views on this thread. Message 15559891 Two differences are that there has been considerable improvement re the elimination of supply constraint issue, and the early approval of Enbrel for psoriatic arthritis is even more likely.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next